Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 172M | 159M | 108M | 24M | 11M |
| Gross Profit | 76M | 85M | 49M | 7M | 3M |
| Operating Income | 3M | 13M | 10M | -23M | -13M |
| EBITDA | 38M | 38M | 35M | -20M | -13M |
| Net Income | -35M | -18M | 15M | -19M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-99.95%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 247 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medicine Man Technologies, Inc. (SHWZ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 100.0% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +8.2%, EPS growth of +46.9%, a dividend yield of 0.0%. What stands out right now is revenue +8.2%, EPS +46.9%, free cash flow +146.4% with operating margin 1.9% and ROIC 1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines SHWZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHWZ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHWZ Max Drawdown
-100.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHWZ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.6M
-55.8% YoY
FY Net Income
-$17.0M
+12.6% YoY
Free Cash Flow
-$7.8M
+26.6% YoY
Revenue Growth
+8.2%
EPS Growth
+46.9%
Gross Margin
44.1%
Net Margin
-20.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 172M | 159M | 108M | 24M | 11M |
| Gross Profit | 76M | 85M | 49M | 7M | 3M |
| Operating Income | 3M | 13M | 10M | -23M | -13M |
| EBITDA | 38M | 38M | 35M | -20M | -13M |
| Net Income | -35M | -18M | 15M | -19M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19M | 39M | 106M | 1M | 12M |
| Total Assets | 358M | 323M | 285M | 71M | 32M |
| Total Liabilities | 239M | 191M | 151M | 29M | 6M |
| Shareholder Equity | 119M | 132M | 134M | 42M | 27M |
| Total Debt | 192M | 148M | 106M | 22M | 67K |
| Net Debt | 173M | 109M | -68K | 20M | -12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+22.9% YoY
Capital Expenditures
200K
+73.9% YoY
Free Cash Flow
8M
+26.6% YoY
Key ratios
Gross Margin
44.1%
Operating Margin
1.9%
Net Margin
-20.0%
ROE
-27.5%
Debt / Equity
1.61x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.